DiaMedica Therapeutics (DMAC) said Wednesday that enrollment of its phase 2/3 trial of DM199 to treat patients with acute ischemic stroke has reached 75% of its target of 1,200 patients.
The biopharmaceutical company said if it reaches 100% enrollment, it will trigger a planned interim analysis. The company also said it still expects the interim analysis to be completed by the end of 2026.
The interim analysis will be conducted by the independent Data Safety Monitoring Board to determine if a sample size re-estimation is recommended for the trial.
Shares of DiaMedica rose more than 2% pre-bell Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments